The international kidney week is right around the corner. From 31 October until 5 November 2017 more than 13.000 kidney professionals from across the globe will come to New Orleans to exchange knowledge about the fight against kidney disease. Acute kidney injury (AKI) is one of the topics and this is also the main focus for one of our SUL compounds.
Sulfateq has developed and patented several unique and potent compounds that form a novel drug class protecting cells from various injuries. The intended use for one of these compounds, SUL-138, is the medical need Acute Kidney Injury (AKI) which is a complication for patients who undergo an of open-heart surgery. AKI effects at least 1.5 million patients a year. Our SUL-138 compound offers a prophylactic treatment for this patient group. Click on this link to read all about the prevention AKI by using our compound.
Do you want more information about our compounds or do you want to discuss possibilities? Please contact us, we are happy to hear from you!